IL-22/IL-22R1 pathway enhances cholangiocarcinoma progression via ERK1/2 activation  

作　　者：Jin Zhou Jing-Rui Chen Jin-Ming Li Shuang-Qing Han Xi-Yue Deng Zhong-Min Li Wen Tong Chao Wang Yi Bai Ya-Min Zhang 

机构地区：[1]The First Central Clinical School,Tianjin Medical University,Tianjin 300192,China [2]Department of Hepatobiliary and Pancreatic Surgery,Tianjin Nankai Hospital,Tianjin 300070,China [3]Department of Hepatobiliary Surgery,Tianjin First Central Hospital,Tianjin 300070,China

出　　处：《World Journal of Gastrointestinal Oncology》2025年第3期246-269,共24页世界胃肠肿瘤学杂志(英文)

基　　金：National Natural Science Foundation of China,No.82372194.

摘　　要：BACKGROUND IL-22 plays a pivotal role in the processes of inflammation and tissue healing.,but its role in cholangiocarcinoma(CCA)remains unclear.our study explored the IL-22/IL-22R1 pathway and its impact on CCA progression through the ERK1/2 signaling cascade.AIM To determine the mechanism of the IL-22/IL-22R1 pathway in CCA and provide new directions for its clinical treatment.METHODS IL-22R1 expression was assessed in human and rat CCA tissues utilizing immunohistochemical techniques,Western blot analysis,and quantitative reverse transcription PCR.The impact of IL-22 on CCA cells was assessed in vitro via tests for proliferation,migration,invasion,and apoptosis assays.The rat models of thioacetamide-induced CCA and subcutaneous xenografts in nude mice were used to assess the in vivo effects.ERK1/2 inhibitors were applied to elucidate the mechanistic role of the pathway.RESULTS IL-22R1 was overexpressed in CCA cell lines and tissues.IL-22 treatment increased the phosphorylation of ERK1/2,promoting tumor cell proliferation,migration,invasion,and resistance to apoptosis.ERK1/2 inhibition considerably reversed these effects both in vitro and in vivo.CONCLUSION The IL-22/IL-22R1 axis promotes CCA progression by activating ERK1/2 signaling.Targeting this pathway with ERK1/2 inhibitors offers potential therapeutic strategies for CCA.

关 键 词：CHOLANGIOCARCINOMA IL-22 IL-22R1 ERK1/2 Cancer progression 

分 类 号：R735.8[医药卫生—肿瘤]